Stocks · Health care · Biological Products, (No Diagnostic Substances)

4D Molecular Therapeutics, Inc.

FDMT Clue Score62

United States Fiscal year ends December CIK 0001650648 Results filed 13 Aug 2026

Add to watchlist

By person

6 insiders · 26 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

David Kirn

See Remarks

—

$5.01M (12) scheduled

−$5.01M

709,153

1.28%

$9.11M

−33.0%

Scott Bizily

Chief Legal Officer

—

$335.83K (9) scheduled

−$335.83K

8,617

0.0156%

$110.64K

−42.7%

Ashoo Gupta

VP, Finance and Controller

—

$6.73K (4) scheduled

−$6.73K

47,055

0.0852%

$604.19K

+3.1%

Ra Capital Management, L.p. entity

10% owner

—

4,563,211

8.26%

$58.59M

−10.5%

Bvf Partners L P/Il entity

See Explanation of Responses

—

87,911

0.1592%

$1.13M

−98.5%

Charles Theuer

Director

—

41,684

0.0755%

$535.22K

+28.8%

4D Molecular Therapeutics, Inc.

What the insiders did Scheduled selling only

By person